Suppr超能文献

相似文献

1
Breast Cancer Cell Detection and Characterization from Breast Milk-Derived Cells.
Cancer Res. 2020 Nov 1;80(21):4828-4839. doi: 10.1158/0008-5472.CAN-20-1030. Epub 2020 Sep 15.
2
Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
PLoS One. 2017 Apr 19;12(4):e0175223. doi: 10.1371/journal.pone.0175223. eCollection 2017.
3
Molecular characterization of CD44/CD24/Ck/CD45 cells in benign and malignant breast lesions.
Virchows Arch. 2017 Mar;470(3):311-322. doi: 10.1007/s00428-017-2068-4. Epub 2017 Jan 23.
6
Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Cell Oncol (Dordr). 2020 Jun;43(3):431-444. doi: 10.1007/s13402-020-00497-6. Epub 2020 Mar 12.
7
Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60. doi: 10.2174/157488809787169110.
8
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
J Clin Pathol. 2011 Nov;64(11):937-46. doi: 10.1136/jcp.2011.090456. Epub 2011 Jun 16.
9
The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
Surg Oncol. 2013 Dec;22(4):217-23. doi: 10.1016/j.suronc.2013.07.001. Epub 2013 Aug 27.

引用本文的文献

1
Redefining "normal": discovery of aneuploid epithelial cells in healthy breast tissue.
Front Oncol. 2025 Jul 31;15:1558977. doi: 10.3389/fonc.2025.1558977. eCollection 2025.
2
Chromatin remodeling and cancer: the critical influence of the SWI/SNF complex.
Epigenetics Chromatin. 2025 Apr 23;18(1):22. doi: 10.1186/s13072-025-00590-w.
3
Challenges and Opportunities in Quantifying Bioactive Compounds in Human Breastmilk.
Biomolecules. 2025 Feb 24;15(3):325. doi: 10.3390/biom15030325.
4
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance.
J Hematol Oncol. 2025 Mar 18;18(1):32. doi: 10.1186/s13045-025-01684-4.
5
Transporters and drug secretion into human breast milk.
Expert Opin Drug Metab Toxicol. 2025 Apr;21(4):409-428. doi: 10.1080/17425255.2025.2461479. Epub 2025 Feb 7.
7
Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer.
Nat Cancer. 2024 Nov;5(11):1622-1640. doi: 10.1038/s43018-024-00816-y. Epub 2024 Aug 28.
8
The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors.
Arch Gynecol Obstet. 2024 Jul;310(1):525-533. doi: 10.1007/s00404-024-07497-z. Epub 2024 May 6.
9
Deciphering a proteomic signature for the early detection of breast cancer from breast milk: the role of quantitative proteomics.
Expert Rev Proteomics. 2024 Jan-Mar;21(1-3):81-98. doi: 10.1080/14789450.2024.2320158. Epub 2024 Feb 23.
10
Structural and functional insights into the epigenetic regulator MRG15.
Acta Pharmacol Sin. 2024 May;45(5):879-889. doi: 10.1038/s41401-023-01211-6. Epub 2024 Jan 8.

本文引用的文献

1
Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer.
NPJ Breast Cancer. 2020 Jun 12;6:24. doi: 10.1038/s41523-020-0165-z. eCollection 2020.
2
Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.
Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5.
3
Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?
Cancer Res. 2020 May 1;80(9):1790-1798. doi: 10.1158/0008-5472.CAN-19-3448. Epub 2020 Feb 19.
4
The Clinical Impact of Cancer Stem Cells.
Oncologist. 2020 Feb;25(2):123-131. doi: 10.1634/theoncologist.2019-0517. Epub 2019 Dec 17.
5
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Nat Genet. 2020 Feb;52(2):198-207. doi: 10.1038/s41588-019-0554-0. Epub 2020 Jan 13.
6
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nat Genet. 2020 Feb;52(2):187-197. doi: 10.1038/s41588-019-0541-5. Epub 2020 Jan 6.
7
The somatic mutation landscape of the human body.
Genome Biol. 2019 Dec 24;20(1):298. doi: 10.1186/s13059-019-1919-5.
8
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers.
Semin Cancer Biol. 2020 Apr;61:180-198. doi: 10.1016/j.semcancer.2019.09.018. Epub 2019 Sep 27.
9
Sentieon DNASeq Variant Calling Workflow Demonstrates Strong Computational Performance and Accuracy.
Front Genet. 2019 Aug 20;10:736. doi: 10.3389/fgene.2019.00736. eCollection 2019.
10
Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.
Cell Res. 2019 Oct;29(10):832-845. doi: 10.1038/s41422-019-0225-9. Epub 2019 Sep 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验